WO2026009141 - IONIZABLE CATIONIC COMPOUND
National phase entry is expected:
Publication Number
WO/2026/009141
Publication Date
08.01.2026
International Application No.
PCT/IB2025/056656
International Filing Date
01.07.2025
Title **
[English]
IONIZABLE CATIONIC COMPOUND
[French]
COMPOSÉ CATIONIQUE IONISABLE
Applicants **
SEQIRUS INC.
Inventors
YANG, Cangjie
Priority Data
63/666,447
01.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4527 | |
| EPO | Filing, Examination, Granting | 46731 | |
| Japan | Filing, Examination, Granting | 3571 | |
| South Korea | Filing, Examination, Granting | 5074 | |
| USA | Filing, Examination, Granting | 39010 |
Total:
98,913
Contact Us
Abstract[English]
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.[French]
L'invention concerne de nouveaux composés lipidiques ionisables de formule I. L'invention concerne l'utilisation des composés dans la formation de nanoparticules lipidiques. Les nanoparticules lipidiques peuvent encapsuler un agent thérapeutique, tel qu'un acide nucléique, et celles-ci peuvent être utilisées dans l'administration de l'agent thérapeutique et dans des méthodes de traitement de certaines affections ou pour induire une réponse immunitaire.